Genius Group has sold its remaining BTC and will consider restarting its bitcoin reserve strategy at an appropriate time in the future.
According to ChainCatcher, as reported by GlobeNewswire, the US-listed company Genius Group (GNS) has released its financial report for the first quarter of 2026 (ending March 31). The company has sold all of its Bitcoin reserves and fully repaid approximately $8.5 million in debt through debt restructuring, stating that it will resume building Bitcoin reserves once market conditions improve.
On the financial front, the company delivered a strong performance in the first quarter: revenue reached $3.3 million, up 171% year-on-year (vs. $1.2 million); gross profit was $2 million, up 228% year-on-year (vs. $600 thousand); and net profit was $2.7 million. The company stated that performance growth mainly came from the full expansion of its three main business lines (Genius School, Academy, Resorts).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
